Please check your internet connection and try again.
# Ezivac Enema
## Overview
Ezivac is a branded formulation of **Sodium Phosphate (Monobasic Sodium Phosphate and Dibasic Sodium Phosphate)**. It functions as a saline osmotic laxative, drawing water into the colon to stimulate peristalsis and evacuation.
## Primary Indications
* Relief of occasional constipation.
* Bowel preparation prior to rectal examinations or surgical procedures.
## Adult Dosing
* **Standard dose:** One 118 mL unit (delivered volume) administered rectally as a single dose.
* **Maximum:** Do not exceed one unit in a 24-hour period.
## Pediatric Dosing
* **Children 12 years and older:** Same as adult dosing (one 118 mL unit).
* **Children 2 to 11 years:** 59 mL (pediatric size unit) administered rectally as a single dose.
* **Children under 2 years:** Contraindicated.
* *Note: Always consult local institutional protocols for specific weight-based requirements in specialized pediatric populations.*
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Increased risk of hyperphosphatemia, hypocalcemia, and hypernatremia. Avoid in patients with clinically significant renal failure.
* **Electrolyte disturbances:** Avoid use in patients with pre-existing electrolyte imbalances.
## Contraindications
* Hypersensitivity to sodium phosphates.
* Congestive heart failure (due to sodium load).
* Presence of bowel obstruction, megacolon, or suspected appendicitis.
* Rectal bleeding of unknown etiology.
* Acute surgical abdomen.
* Severe renal impairment.
## Adverse Effects
* **Common:** Rectal irritation, abdominal cramping, nausea.
* **Serious:** Severe electrolyte disturbances (hyperphosphatemia, hypocalcemia, hypokalemia, hypernatremia), dehydration, acute phosphate nephropathy, and cardiac arrhythmia (secondary to electrolyte shifts).
## Key Drug Interactions
* **Diuretics (loop/thiazide):** Increased risk of dehydration and electrolyte imbalances.
* **ACE Inhibitors/ARBs:** Increased risk of nephrotoxicity and electrolyte derangement.
* **NSAIDS:** May potentiate renal risk.
* **Calcium Channel Blockers:** Potential for enhanced hypocalcemic effects.
## Monitoring
* Monitor fluid and electrolyte status in elderly or frail patients.
* Observe for signs of dehydration (thirst, decreased urine output, orthostasis).
* Ensure prompt passage of stool; if no evacuation occurs within 30 minutes, discontinue use and consult a physician to avoid phosphate toxicity.
## Clinical Pearls
* **Positioning:** Patient should be in the left lateral decubitus position (Sims' position) for administration.
* **Avoid forceful insertion:** Excessive force may cause rectal trauma or perforation, particularly in patients with pre-existing hemorrhoids or anal fissures.
* **Hydration:** Encourage adequate oral fluid intake prior to and after administration to prevent dehydration.
* **Overuse:** Chronic use can lead to dependency and electrolyte depletion.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug formulations may vary by region. Always verify specific dosing, safety warnings, and contraindications against the current manufacturer’s prescribing information and your institution's specific clinical protocols before prescribing or administering medication.
